A Milestone Moment: HiveBio Celebrates a Successful First-Ever Investor Showcase
- Caroline Okun
- Dec 4
- 2 min read
Yesterday, on December 3, we marked a major milestone with the first-ever HiveBio Investor Showcase, presented by MilliporeSigma. The event brought together investors, industry leaders, mentors, and community partners in a sold-out room that demonstrated just how much momentum is building around inclusive biotech entrepreneurship.
Thanks to the remarkable energy of everyone who attended — and the hard work of our founders — the showcase was a huge success. Attendees heard investor-ready pitches from the companies in HiveBio’s inaugural cohort, engaged in thoughtful Q&A, networked with peers across the life sciences community, and joined founders for a lively Meet & Greet and tours of BioLabs’ newly expanded 8th floor. A heartfelt congratulations goes out to Cohort 1, whose clarity of vision and scientific rigor shone throughout the day, and a special thank you to BioLabs for hosting us in their beautiful space. And of course, Knight Foundation for believing in us and their initial investment of $250K.
"HiveBio resonated with our journey to build fearlessly for patients, especially because working with their experts helped us clarify our problem, refine our vision, and learn from both founders and investors. I’m truly grateful for the experience." — Mohit Sachdeva, PhD, MBA, Founder & CEO of Ajaya Bio
HiveBio’s Impact: Early Results, Real Momentum
The showcase also served as a moment to reflect on the extraordinary progress HiveBio companies have made during the program. We are proud to share these major milestones:
10x Return Rate in Fundraising Support
Among startups raising at least $250K, participation in HiveBio translated into a tenfold return on the resources and guidance they received—highlighting the accelerator’s ability to convert early support into meaningful capital outcomes.
80% Success Rate in Fundraising Support
HiveBio now has an 80% success rate in helping our startups secure funding — an incredible achievement for a first-year cohort of underrepresented biotech founders.
$3.56M+ Raised to Date
Collectively, companies in Cohort 1 have raised $3.56M+ during their time with us. This includes both initial investments and additional fundraising since September 2025.
Current funding totals include:
BioLattice Ophthalmics — $590K
Higher Medicine — $200K
Vasowatch — $600K
DRS.LINQ — $425K
Bound Therapeutics — $507K
Trevarx Biomedical — $390K
Ajaya Bio — $550K
Valfard Therapeutics — $300K
These numbers represent not just financial traction, but the growing confidence from investors in the transformative science and strong leadership emerging from HiveBio’s inaugural cohort.
Gratitude & What Comes Next
We are profoundly grateful to MilliporeSigma for sponsoring this first annual showcase and for their commitment to empowering early-stage biotech companies. Their support — alongside the participation of our mentors, investors, attendees, and the BioLabs team — made this milestone possible.
